PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - A First for Any RP11 Treatment To-Date
- Category: DNA RNA and Cells
- Published on Tuesday, 02 March 2021 15:22
- Hits: 571
Retinal Pigment Epithelium is the Structure that Provides the Critical Blood-Retinal Barrier in Healthy Eyes and is the Structure that is Compromised in Retinitis Pigmentosa Type 11
VP-001 is the First and Only Treatment to Demonstrate Restoration of this Critical Barrier Function in a Patient-Derived Model
This Result Builds Further Confidence that VP-001 will have Meaningful Clinical Impact for Patients and Highlights the Competitive Advantages of PYC's RNA Approach over Other Genetic Medicine Approaches
NEW YORK, NY, USA and PERTH, Australia I March 2, 2021 I PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced that the Company's lead investigational drug, VP-001, for the treatment of RP11 has restored function of the Retinal Pigment Epithelium, the target cells for the therapy, in patient-derived models of the disease.
"This result builds further conviction in VP-001 as we head towards clinical testing. Break-down of the Blood-Retina Barrier is a major driver of vision loss in patients with RP11. This result has given us the best non-clinical demonstration that VP-001 has the potential to correct this problem in patients," commented PYC's U.S. Chief Executive Officer Sahm Nasseri.
The Retinal Pigment Epithelium (RPE) cells create a barrier around the outside of the eye when the RPE cells join together through 'tight-junctions' that form between individual RPE cells. This 'layer' of RPE cells form the outer Blood-Retina Barrier (BRB) (Figure 1) that prevents fluid from leaking into and damaging the retina.
"The individual RPE cells act like bricks in a dam; they all work together in stopping large amounts of fluid flowing directly into the retina. At the same time, they allow for the controlled flow of nutrients to keep the retina functioning and enable normal vision," commented PYC's Chief Scientific Officer Prof. Sue Fletcher.
In patients with RP11, two elements of the RPE function are lost:
- The functionality of individual RPE cells (PYC's VP-001 has previously shown effectiveness in correcting this loss of function, see ASX announcements of April 1 and December 16, 2020); and
- The role of the RPE monolayer in the BRB. The barrier function of this monolayer is created through tight-junctions that form between all the RPE cells. If only a few of these tight-junctions fail, then the integrity of the whole BRB is comprised – just like taking a few bricks out of a dam wall.
VP-001 has now demonstrated an ability to restore the integrity of the blood-retina barrier that is lost in patients with the disease, in models derived from patients with RP11 (Figure 2). This development indicates that VP-001 can more comprehensively address the mechanisms of the disease that lead to visual loss in patients with RP11 than alternative therapies tested to-date. These data provide the first evidence of restoration of the barrier function of the RPE monolayer and add to the previously released efficacy data for VP-001 demonstrating an ability to correct the functional deficits seen in individual RPE cells in patients with RP11 (see ASX announcements of April 1 and December 16, 2020).
This achievement differentiates PYC's RNA approach from Adeno-Associated Virus (AAV) delivered DNA therapies directed towards the treatment of RP11 that have not been able to demonstrate an improvement in these functional endpoints in non-clinical testing1.
In addition to the results supporting improved barrier function of the RPE monolayer, correction of the morphology (the 'structure' of the cell) is shown after treatment with VP-001 (Figure 3). This quantifies the visual evidence of the improvement PYC demonstrated after treatment with VP-001 (see ASX announcement of December 16, 2020).
"Patients with RP11 are desperately waiting for a treatment option. These data shared today represent exciting progress for VP-001 as PYC strives to elucidate the potential of this breakthrough RNA agent as we advance towards the clinic. Beyond these results, we look forward to sharing continued progress for VP-001 through our important large animal studies in the middle of 2021, with the goal of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) during the first half of 2022," concluded Sahm Nasseri.
About PYC Therapeutics
PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize Cell Penetrating Peptides (CPPs), a revolutionary delivery technology designed to overcome the major challenges of current gene-based therapies. PYC believes its CPP technology provides safer, more effective access for a wide range of potent and precise drug cargoes to the highest value drug targets that exist inside cells. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies with an initial focus on inherited eye diseases for which it has unveiled three preclinical stage assets. PYC's discovery and laboratory operations are located in Australia and the Company recently launched and expansion into the U.S. for its preclinical, clinical, regulatory and business development operations. For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.
SOURCE: PYC Therapeutics